Fact check · Version 1 · Sources checked
“The 2026 advisory vote added DSIP to the 503A list or approved it.”
The Peptide Field explains research. Its pages are not independently medically reviewed, and they do not diagnose, prescribe, or recommend treatment.
Misleading
This statement leaves out a limit that changes its meaning.
The July 2026 committee vote was advisory. It did not itself change the 503A list or approve a drug. The current U.S. list does not show DSIP or emideltide, and no final FDA approval was identified in this review.
- What this answer is based on
- This answer uses an official regulator record or a specific product label.
- Limits of this answer
- The July 2026 advisory vote and United States 503A status as reviewed August 30, 2026; an advisory recommendation is not a final FDA decision or drug approval. These limits show which substance, product, people, use, place, and time the answer covers. A different product or situation can have a different answer.
- Topic
- Whether a specific product has an approval or another official status.
Sources for this fact check
Show 3 sources
01July 23-24, 2026 Pharmacy Compounding Advisory Committee meetingU.S. Food and Drug Administration · Regulatory · 202602FDA evaluation of emideltide (DSIP) and related bulk drug substancesU.S. Food and Drug Administration · FDA review · 20260321 CFR 216.23 bulk drug substances listElectronic Code of Federal Regulations · Regulatory · 2026
- Sources checked by
- Site editor · Editorial review